[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-transplant-recipient\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-transplant-recipient":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,82,115,143,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100647856","phase-2-cemiplimab-for-kidney-transplant-recipients-with-advanced-cutaneous-squamous-cell-carcinoma-100647856",false,"NCT07715734","Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma","A Phase 2 Study of Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC-2)","CONTRAC-2","Inclusion Criteria:\n\n* Histologically confirmed locoregionally advanced and unresectable or recurrent\u002Fmetastatic cutaneous squamous cell carcinoma (CSCC). Definitions that encompass unresectable disease include any of the following, after discussion at the multidisciplinary meeting:\n\n  * Anatomically unresectable disease to include carotid artery encasement; invasion into the skull base, cavernous sinus, sagittal sinus; pre-vertebral fascia\u002Fvertebral body\u002Fvertebral artery; disseminated distant metastatic disease\n  * Functionally unresectable disease resulting in the loss of sight, oral competency\u002Fspeech\u002Fswallowing, or limb\n  * Biologically unresectable disease to include satellitosis, in-transit\u002Fdermal metastasis, or disease which has failed 2 or more prior surgeries (by an experienced CSCC surgeon) or failed curative intent radiation therapy\n* Measurable disease per RECIST 1.1.\n* Received a kidney transplant. Must have a functioning allograft, be at least 6 months from last allograft transplantation, and have had no evidence of biopsy-proven allograft rejection (Banff 1A or above, requiring treatment) at any time. In order to be considered a functioning allograft, the following criteria must be met:\n\n  * Estimated glomerular filtration rate (GFR) ≥ 30 mL\u002Fmin (using the CKD-EPI equation either by Cr or Cystatin C based measurement) (Inker LA et al, 2021)\n  * Baseline proteinuria \\\u003C 0.5 g\u002Fday (by spot urine protein-creatinine ratio or 24-hr urine collection, if available)\n  * Not receiving antiproliferative immunosuppressive medications. If patients are on antiproliferative immunosuppressive medications, they must be discontinued for at least 7 days before initiation of C1D1 (i.e. at the screening visit and\u002For during the lead-in period)\n* At least 18 years of age.\n* ECOG performance status ≤ 2\n* Adequate bone marrow and organ function as defined below:\n\n  * Leukocytes ≥ 2.2 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 90 K\u002Fcumm\n  * Total bilirubin within normal institutional limits (except in cases where Gilbert syndrome is known or suspected, where total bilirubin should be \\\u003C 3 mg\u002FdL)\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.5 x IULN\n* The effects of cemiplimab on the developing human fetus are unknown. For this reason, people of childbearing potential and people able to father a child must agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 4 months after last dose of cemiplimab.\n* Able to switch immunosuppression regimen to sirolimus and prednisone if not already receiving sirolimus and prednisone as SOC.\n* Able to understand and willing to sign an IRB approved written informed consent document and willing and able to comply with clinic visits and study-related procedures. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Received chemotherapy or radiotherapy within 2 weeks prior to C1D1. Note: prior cetuximab exposure is permitted, but it must have been discontinued at least 2 weeks prior to the start of cemiplimab.\n* Received prior anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CLTA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways (including chimeric antigen receptor \\[CAR\\] T-cell therapies).\n\nNote: prior topical or intralesional immunotherapies (e.g., imiquimod, talimogene laherparepvec) are permitted.\n\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial\n* Currently receiving any other investigational agents.\n* Unable to swallow pills.\n* Currently receiving any medications or substances that are strong inhibitors or inducers of CYP3A4.\n* Receipt of a live vaccine within 28 days of C1D1.\n* Receipt of COVID-19 vaccination within 7 days of C1D1 or for which the planned COVID-19 vaccinations would not be completed 7 days prior to C1D1.\n* Patients with untreated brain metastases. Patients with treated brain metastases are allowed if post-treatment brain-imaging after CNS-directed therapy shows no evidence of progression and if they are at least 4 weeks out from treatment. They must also be asymptomatic and on stable doses of anti-epileptic drugs (AEDs) and oral corticosteroids at the time of enrollment\n* A history of allergic reactions attributed to or known hypersensitivity to cemiplimab or any of its components or other agents used in the study.\n* Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments. Note: the following are not exclusionary: vitiligo, childhood asthma that has resolved, endocrinopathies (such as hypothyroidism or type 1 diabetes) that require only hormone replacement, or psoriasis that does not require systemic treatment. Patients with a history of Hashimoto thyroiditis who are stable on replacement hormone therapy are not excluded.\n* Any condition that requires ongoing\u002Fcontinuous corticosteroid therapy (\\> 10 mg prednisone\u002Fday or anti-inflammatory equivalent) within 7 days prior to C1D1. Patients who require a brief course of steroids (up to 2 days in the week before C1D1) or physiologic replacement are not excluded.\n* Uncontrolled intercurrent illness including but not limited to ongoing or active infection requiring hospitalization or treatment with IV anti-infectives within 14 days prior to C1D1; NYHA heart failure classifications of Class II, III, or IV; myocardial infarction or acute coronary syndrome within 12 months prior to C1D1; unstable angina pectoris; cardiac arrhythmia; transient ischemic attack or stroke within 12 months prior to C1D1.\n* Known non-infectious pneumonitis or any history of interstitial lung disease.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry.\n* Uncontrolled infection with HIV, hepatitis B or C infection, diagnosis of immunodeficiency, and\u002For tuberculosis (active or latent).\n\n  * Participants with known controlled HIV infection (undetectable viral load on HIV RNA PCR) and CD4 count \\> 350 either spontaneously or on a stable antiviral regiment are eligible. For these participants, monitoring will be performed as per local standards.\n  * Participants with HBsAg positive who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are eligible. Participants with controlled infections must undergo periodic monitoring of HBV DNA. Participants must remain on anti-viral therapy for at least 6 months beyond the last dose of cemiplimab.\n  * Participants with HBsAg negative but total HBcAb positive are permitted with the following requirements: if serum HBV DNA is above the limit of detection at screening, initiate HBV antiviral therapy before study entry. If serum HBV DNA PCR is below the limit of detection, periodic monitoring of HBsAg must be performed.\n  * Participants who are HCV Ab+ who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are eligible.","ALL","18 Years",{"count":20,"type":21},22,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma. The hypothesis being tested is that cemiplimab alongside standardized immune suppression will generate anti-tumor activity without triggering allograft rejection.",[27,28,29,30],"Kidney Transplant Recipient","Cutaneous Squamous Cell Carcinoma (CSCC)","Advanced Cutaneous Squamous Cell Carcinoma","Kidney Transplant",[32,33,34],"Cutaneous squamous cell carcinoma","Advanced cancer","Kidney transplant","NOT_YET_RECRUITING","2026-07-11",{"date":38,"type":39},"2026-07-20","ACTUAL",{"date":41,"type":21},"2026-09-30",{"date":43,"type":21},"2031-03-31",{"name":45,"class":46},"Washington University School of Medicine","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100645401","phase-2-sglt2i-effect-on-ptdm-development-and-kidney-allograft-function-in-non-diabetic-kidney-transplant-recipients-a-randomized-doubleblind-placebo-controlled-national-multicenter-trial-100645401","NCT07682350","SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial","SGL-TX-PTDM: SGLT2i Effect on PTDM Development and Kidney Allograft Function in Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial","SGL-TX-PTDM","Inclusion Criteria:\n\n* Obtained written informed consent\n* Male or female patients, age ≥ 18 years.\n* Non-diabetic KTR\n* Immunosuppressive must include Tacrolimus\n\nExclusion Criteria:\n\n* Patients who is treated (diet or antidiabetics) for diabetes type 1 or 2 before randomization\n* eGFR\\\u003C 25 ml\u002Fmin\u002F1.73m2 (before randomization)\n* Alanine aminotransferase (ALAT) \\> 3 x upper normal limit\n* Bilirubin \\> 2 x upper normal limit\n* Pregnancy\n* Positive plasma hCG\n* Breastfeeding\n* Known allergy towards SGLT2i or the content substance\n* Patients with chronic intestinal diseases, including inflammatory bowel diseases (e.g., Crohn's disease and ulcerative colitis) and structural conditions such as short bowel syndrome.",{"count":57,"type":21},184,[24],"The goal of this clinical trial is to find out whether 12 months of treatment with the SGLT2 inhibitor Forxiga® (dapagliflozin 10 mg once daily), compared with placebo, can reduce the risk of developing post-transplant diabetes in kidney transplant recipients who do not have diabetes at the time of transplantation.\n\nThe main questions it aims to answer are:\n\n* Does Forxiga reduce the risk of developing post-transplant diabetes and prediabetes compared with placebo?\n* Does Forxiga help preserve the function of the transplanted kidney compared with placebo?\n* Is Forxiga safe for kidney transplant recipients who do not have diabetes?\n* Does Forxiga affect the occurrence of urinary tract infections, the amount of protein in the urine, and other kidney- and heart-related health measures compared with placebo?\n\nResearchers will compare Forxiga with a placebo (a look-alike tablet containing no active medicine) to see whether it can reduce the risk of post-transplant diabetes while maintaining kidney function and remaining safe to use.\n\nAdults who have recently received a kidney transplant and do not have diabetes may take part if they meet the study requirements.\n\nParticipants will be randomly assigned to receive either Forxiga or placebo once daily for 12 months. They will attend study visits 3, 6, and 12 months after joining the study. These visits will include health checks, blood tests, and urine tests. Neither the participants nor the study doctors will know which treatment each participant is receiving.",[27,61,62,63,64,65],"Sodium Glucose Co-Transporter 2 Inhibitors","Non-Diabetic Patients","Randomized Controlled Trial (RCT)","Placebo Control Design","Post Transplant Diabetes Mellitus",[67,30,68,69,70,71,54],"SGLT2i","Kidney Transplant Recipients","non-diabetic patients","Sodium-glucose Transporter 2 inhibitors","RCT","2026-06-26",{"date":74,"type":39},"2026-07-02",{"date":76,"type":21},"2026-09-01",{"date":78,"type":21},"2029-10-01",{"name":80,"class":46},"Odense University Hospital",3,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":102,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":81},"100633844","vascular-complications-after-kidney-transplantation-100633844","NCT07531966","Vascular Complications After Kidney Transplantation","Vascular Complications After Kidney Transplantation: A Prospective National Multicenter Study - The DAN-PTRAIII Study","DAN-PTRAIII","Inclusion Criteria:\n\n1\\. At least one of the following clinical criteria (1 or 2) must be fulfilled:\n\n1. Graft dysfunction, defined by at least one of the following:\n\n   * Acute reduction in estimated glomerular filtration rate (eGFR) \\>15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).\n   * eGFR \\\u003C50% of the expected value 30 days after kidney transplantation of unknown cause.\n   * Decline in eGFR \\>30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.\n2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:\n\n   * 24-hour ambulatory systolic blood pressure \\>130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).\n\nTogether with at least one of the following radiological criteria:\n\n1. CT or MR angiography demonstrating a lumen reduction ≥50%.\n2. Doppler ultrasound showing:\n\n   1. Peak systolic velocity in the renal artery ≥200 cm\u002Fs and a renal renal ratio (velocity at stenosis \u002F velocity in distal artery) \\>4.\n   2. Acceleration time \\>70 ms in intrarenal arteries.\n\n2\\. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.\n\nBefore PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:\n\n1. Stenosis ≥70%.\n2. Stenosis 50-69% if at least one of the following criteria is met:\n\n   * Mean translesional pressure gradient ≥10 mmHg.\n   * Systolic pressure gradient ≥20 mmHg.\n   * Renal Pd\u002FPa ≤0.8.\n   * If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent.\n2. Concurrent biopsy demonstrating rejection requiring treatment.\n3. Pregnancy.\n4. Previous PTA of the same vessel.\n5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.",{"count":91,"type":21},60,"10 Years","OBSERVATIONAL","* To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and\u002For treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.\n* To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.\n* To assess whether novel imaging and functional diagnostic methods can predict treatment response.",[27,96,97,98,99,100,101],"Kidney Transplant; Complications","Transplant Renal Artery Stenosis","Renovascular Disease","Renal Transplant Graft Failure","Renovascular Hypertension","Heart Failure",[96,97,103,104],"renovascular disease","Percutaneous transluminal angioplasty","RECRUITING","2026-05-26",{"date":108,"type":39},"2026-05-27",{"date":110,"type":39},"2026-05-22",{"date":112,"type":21},"2031-06-01",{"name":114,"class":46},"University of Aarhus",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":47},"100630500","early-phase-1-renal-ex-vivo-syn002-perfusion-to-eliminate-cmv-transmission-100630500","NCT07488481","Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission","Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission: A Safety Trial in Kidney Transplant Recipients","RESPECT-CMV","Recipient Inclusion Criteria:\n\n* Age ≥18 years\n* Listed for kidney transplantation\n* Either CMV seronegative or seropositive\n* Willing to provide written informed consent to take part in the trial\n* Willing and able to return for follow-up visits as scheduled in the protocol\n* Not participating in other interventional trials\n\nRecipient Exclusion Criteria:\n\n* Listed for combined organ transplant (e.g. kidney-pancreas or kidney-liver)\n* Re-transplantation\n* HIV positive\n* Highly sensitized recipient with a PRA \\>=95\n* Planned use of belatacept or alemtuzumab immunosuppression (both non-approved drugs in Canada)\n* Unable or unwilling to comply with study procedures\n\nDonor Inclusion Criteria:\n\n* Deceased donor\n* CMV seropositive (D+)\n* Donor kidney meets criteria for transplantation\n* Single renal artery (required anatomy to perform EVOP)\n\nDonor Exclusion Criteria:\n\n* CMV seronegative\n* Donor kidney not suitable for transplantation",{"count":124,"type":21},12,[126],"EARLY_PHASE1","Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).",[129,27],"Cytomegalovirus (CMV) Infection",[131,132,133],"Cytomegalovirus","Kidney Transplantation","Ex-vivo organ perfusion","2026-03-17",{"date":136,"type":39},"2026-03-23",{"date":138,"type":21},"2026-03-16",{"date":140,"type":21},"2027-12-31",{"name":142,"class":46},"University Health Network, Toronto",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100586257","phase-2-semaglutide-for-the-prevention-of-post-transplant-diabetes-mellitus-100586257","NCT06913023","Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus","SPOT-DM","Inclusion Criteria:\n\n1. Signed and dated written informed consent.\n2. Adult (≥18 years) recipients of a living or deceased donor kidney transplant\n3. Between 4- and 12-weeks post kidney transplant\n4. Stable kidney function defined as an eGFR \\> 30 ml\u002Fmin\u002F1.73m2 (CKD-EPI)\n5. At risk for PTDM at the time of transplant based on the following criteria:\n\n   1. BMI ≥ 25 kg\u002Fm2, or\n   2. Fasting plasma glucose 6.1-6.9 mmol\u002FL (impaired fasting glucose), or\n   3. 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or\n   4. HbA1C 5.5-6.4% (at risk for DM or prediabetes).\n\nExclusion Criteria:\n\n1. Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)\n2. Kidney-Pancreas transplant recipient\n3. Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening\n4. History of pancreatitis\n5. Personal or family history of medullary thyroid cancer or MEN2B\n6. Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial\n7. Use of GLP1RA in the 30 days prior to screening\n8. Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)\n9. With known or suspected hypersensitivity to semaglutide or related products\n10. Patient not able to understand and comply with study requirements, based on Investigator's judgment.\n11. Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom\n12. History of glucose-galactose malabsorption syndrome",{"count":151,"type":21},74,[24,153],"PHASE3","The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).",[27],"2025-04-02",{"date":158,"type":39},"2025-04-06",{"date":160,"type":21},"2026-01-05",{"date":162,"type":21},"2027-11-30",{"name":142,"class":46},2,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":190,"locationsCount":47},"100582037","outcomes-of-a-pre-operative-exercise-programme-for-live-donor-and-recipient-kidney-transplant-patients-100582037","NCT06858098","Outcomes of a Pre-operative Exercise Programme for Live Donor and Recipient Kidney Transplant Patients","Outcomes of a Pre-operative Exercise Regimen for Patients Undergoing Hand-assisted Liver Donor Nephrectomy and Transplantation","OPERATe","Inclusion Criteria:\n\n* Aged 18 years and over\n* Live kidney donor or transplant recipient\n\nExclusion Criteria:\n\n* Deceased donor transplant recipient\n* Patient unable to wear or tolerate wearable device\n* Unstable angina, recent myocardial infarction, recent cerebrovascular accident or new arrythmia\n* Patient declines or is unable to participate in the exercise programme\n* Lacks capacity to give informed consent to participate in trial\n* Non-English speaking\n* No access to a smart device to download application",{"count":174,"type":21},40,[176],"NA","The goal of this clinical trial is to learn if a pre-operative outpatient exercise programme, monitored by a smart wearable device is acceptable to live kidney donor and recipient transplant patients. It will also look at the impact of prehabilitation on post operative outcomes. The main questions it aims to answer are:\n\nIs it feasible for renal transplant patients and live kidney donors to participate in a prehabilitation programme in combination with a piece of wearable technology?\n\nAre transplant outcomes improved by prehabilitation regimens delivered by video instruction?\n\nAre there discernible perioperative digital signatures provided by the wearable that link to surgical outcomes?\n\nIs the quality of perioperative sleep linked to surgical outcomes?\n\nParticipants will:\n\nWear a wrist or ring worn wearable device for a total of 14 weeks (2 week baseline, 6 week pre op and 6 week post op) Engage in a 6 week pre operative exercise programme at home\u002Fgym Keep a diary and answer surveys on their experience of the exercise regimen and wearable device",[30,179,27],"Kidney Transplant Donor",[181,182,183],"live kidney transplant","prehabilitation","wearable devices","2025-03-24",{"date":186,"type":39},"2025-03-25",{"date":188,"type":21},"2025-05-01",{"date":76,"type":21},{"name":191,"class":46},"University of Manchester"]